Hepatitis C Virus (HCV) Infection May Elicit Neutralizing Antibodies Targeting Epitopes Conserved in All Viral Genotypes

Nicasio Mancini1,*, Roberta A. Diotti1,*, Mario Perotti1, Giuseppe Sautto1, Nicola Clementi1, Giovanni Nitti1, Arvind H. Patel2, Jonathan K. Ball3, Massimo Clementi1, Roberto Burioni1

1 Laboratorio di Microbiologia e Virologia, Università “Vita-Salute” San Raffaele, Milano, Italia, 2 MRC Virology Unit, Institute of Virology, University of Glasgow, Church Street, Glasgow, United Kingdom, 3 Institute of Infection, Immunity and Inflammation, School of Molecular Medical Sciences, University of Nottingham, Queen’s Medical Centre, Nottingham, United Kingdom

Abstract

Anti-hepatitis C virus (HCV) cross-neutralizing human monoclonal antibodies, directed against conserved epitopes on surface E2 glycoprotein, are central tools for understanding virus-host interplay, and for planning strategies for prevention and treatment of this infection. Recently, we developed a research aimed at identifying these antibody specificities. The characteristics of one of these antibodies (Fab e20) were addressed in this study. Firstly, using immunofluorescence and FACS analysis of cells expressing envelope HCV glycoproteins, Fab e20 was able to recognize all HCV genotypes. Secondly, competition assays with a panel of mouse and rat monoclonals, and alanine scanning mutagenesis analyses located the e20 epitope within the CD81 binding site, documenting that three highly conserved HCV/E2 residues (W529, G530 and D535) are critical for e20 binding. Finally, a strong neutralizing activity against HCV pseudoparticles (HCVpp) incorporating envelope glycoproteins of genotypes 1a, 1b, 2a, 2b and 4, and against the cell culture-grown (HCVcc) JFH1 strain, was observed. The data highlight that neutralizing antibodies against HCV epitopes present in all HCV genotypes are elicited during natural infection. Their availability may open new avenues to the understanding of HCV persistence and to the development of strategies for the immune control of this infection.

Introduction

The hepatitis C virus (HCV) infection is presently a major public health problem, and nearly 3% of the world population is persistently infected with this virus [1,2]. At least six major HCV genotypes and more than 50 subtypes have been described based on nucleotide diversity of the core, E1/E2, and NS5 regions [3,4,5]. Moreover, HCV infection is characterized by high intra-host variability, due to high mutation rate and replication activity in vivo. As a direct consequence of this variability, each HCV-infected patient harbours a population of related, but genetically distinct viral variants. It is presently believed that HCV variability strongly determines virus persistence in the infected hosts, allowing its escape from the immune system [6,7,8].

Despite almost two decades of studies, no vaccine is presently available to prevent infection with this virus. Efforts aimed at developing an anti-HCV vaccine have been hampered by the high virus variability, the substantial lack of readily available animal models, and the absence of clearly established in vitro correlates of protective immunity. It is currently believed that CD4+ and CD8+ T-cell responses are central in the control of acute HCV infection. Otherwise, the role of anti-HCV humoral response is still controversial [9,10,11]. However, recent data have suggested that neutralizing anti-HCV antibody responses may strongly influence the natural course of HCV infection. In this context, an effective immunization against HCV calls for induction of both robust T- and B-cell responses. As far as the latter point is concerned, this result is possible if new immunogens are designed, capable of eliciting broadly reacting and neutralizing antibodies.

Recently, the availability of viral pseudotypes bearing surface HCV glycoproteins (E1 and E2) has offered a reliable model system to evaluate in vitro the anti-HCV neutralizing activity of polyclonal sera and monoclonal antibodies. Using this approach, it has been shown that neutralizing activity is detectable in sera from a significant proportion of infected patients during primary and persistent HCV infection [12,13], and that the presence of high titres of neutralizing antibodies directed against conserved epitopes may influence the virus-host interplay during all stages of the infection [14,15,16,17,18]. In the last few years, we have used phage-display to dissect the antibody response of HCV-infected patients, searching for potentially cross-reactive Fabs directed against HCV/E2. Using this approach, we have obtained several cross-reactive anti-HCV/E2 human mAbs endowed with different biological characteristics [19,20,21,22,23,24,25]. In the study shown here, we evaluated the binding characteristics of a human monoclonal Fab (named e20) that was able to bind E2
glycoproteins of all tested genotypes. Notably, this Fab was able to cross-neutralize HCVpp containing E1\E2 from different genotypes.

Materials and Methods

Ethics Statement
Previous studies, that allowed the cloning of the human monoclonal antibody used in this research, were approved by the University Vita-Salute Ethical Committee. However, the present study, not presenting experiments on animals, human samples, or patients, and being based on a recombinant protein expressed in a bacterial vector, did not specifically require a formal adjunctive approval.

Analysis of the Binding Activity

The binding activity of anti-HCV/E2 monoclonal Fab e20 was assayed using recombinant HCV/E2 proteins derived from different genotypes. The following isolates were used: genotype 1a (isolate H77.20); 1b (UKN1B12.16); 2a (UKN2A.2.4); 2b (UKN2B.8); 3 (UKN3A1.28c); 4 (UKN4.21.16); 5 (UKN5.15.11) and 6 (UKN6.5.8). In brief, human epithelial kidney (HEK) 293T cells were transfected with 3 μg of pcDNA3.1 vector [5], an expression vector encoding surface glycoproteins of the above listed HCV isolates [26]. After centrifugation, fixation and permeabilization, the transfected cells were incubated with e20 (10 μg/ml). After further washings, the cells were incubated with a FITC-conjugated anti-human Fab monoclonal antibody, and analysed by fluorescent microscopy and by FACS. Untransfected cells and a human recombinant Fab (c33-3) specific for a non-structural antigen of HCV (NS3) were also included in each experiment as negative controls [27].

A mouse broadly cross-reactive monoclonal (AP33) was used to analyze the transfection efficiency for each genotype. The percentage of AP33-incubated sorted cells featuring a higher fluorescence signal than untreated cells was comparable for all different genotypes (approximately 70% of 10,000 cells analysed by FACS).

The binding activity of e20 against the different genotypes was then expressed as percentage of the reactivity observed on genotype 1a (relative binding activity), measured by sorting for each genotype the number of cells featuring a higher fluorescence signal than cells without Fab. The fluorescence obtained using e20 on untransfected cells was subtracted as background.

Epitope Characterization: Competition ELISA

In order to map the e20 epitope, competition ELISA assays were performed using a panel of well-characterized murine and rat monoclonals (Table 1). Competition experiments were conducted reciprocally, as previously described [19], using plates coated with HCV/E2 of genotype 1a (4 μg/ml). In brief, Fab e20 was titrated and used as probe at a concentration giving 50% of maximum binding, whereas all competing mAbs were used at a saturating concentration. In this case, a horse radish peroxidase (HRP)-conjugated anti-human IgG Fab polyclonal was used to detect Fab 20 binding on HCV/E2. Alternatively, each mouse or rat monoclonal was used as probe at a concentration giving 50% of maximum binding, and Fab e20 was used at a saturating concentration. In this case, HRP-conjugated anti-mouse or anti-rat IgG polyclonals were used to detect the binding on HCV/E2. Final results were determined as percent inhibition with the following formula: percent inhibition = 100 × [(OD<sub>150</sub> of probe Fab alone−OD<sub>150</sub> of probe Fab with competitor Fab)/OD<sub>150</sub> of probe Fab alone].

| Competing mAbs | HCV/e2 epitope | e20 |
|----------------|----------------|-----|
| 7/59           | 384–391        | 3   |
| 3/11           | 412–423        | 5   |
| AP33           | 412–423        | 40  |
| 1/39           | 436–443        | 57  |
| 11/20          | 436–447        | 4   |
| 7/16b          | 436–447        | 5   |
| H47            | 452–459        | 4   |
| 6/1a           | 464–471        | 2   |
| 6/41a          | 480–493        | 5   |
| 2/64a          | 524–531        | 32  |
| 9/75           | 528–535        | 76  |
| 6/53           | 544–551        | 4   |
| H62            | 644–655        | 2   |

The results were confirmed in a reciprocal competition assay, using each mouse and rat monoclonal as a probe. Data are expressed as % of inhibition. doi:10.1371/journal.pone.0008254.t001

Epitope Characterization: Binding Experiments on Point-Mutated HCV/E2 Clones

To define better the critical E2 residues involved in binding, the reactivity of Fab e20 to a panel of alanine point-mutated H77-derived HCV/E1-E2 (1a) clones [20] was determined. Five of

Figure 1. Binding activity of Fab e20 on E1E2 derived from different HCV genotypes. The following strains were used: genotype 1a (isolate H77.20); 1b (UKN1B12.16); 2a (UKN2A.2.4); 2b (UKN2B.8); 3 (UKN3A1.28c); 4 (UKN4.21.16); 5 (UKN5.15.11) and 6 (UKN6.5.8). The broadly cross-reactive monoclonal AP33 was used to assess that the efficiency of transfection was comparable for all different genotypes. Binding activity for each genotype is expressed as percentage of the reactivity observed on E1E2 of genotype 1a (H77 strain). The means and standard errors of two replicate assays are reported. doi:10.1371/journal.pone.0008254.g001
these mutants (W420A, Y527A, W529A, G530A, D535A) completely inhibit HCV/E2 binding to CD81 also abrogating the infectivity of HCV pseudoparticles [28]. Differences in e20 binding to wild type H77 and to each mutant were determined by FACS, following the protocol described above. In this approach, the ALP98 mouse mAb (directed against a linear epitope outside the mutated regions) [29] was used to evaluate the expression level of the mutated E1E2.

Neutralization Assays on HCV Pseudoparticles (HCVpp) and on HCV Cell Culture Infectious Viral Particles (HCVcc)

The neutralizing activity of Fab e20 was tested using a HCV pseudoparticle (HCVpp)-based neutralization assay, following already described protocols [26]. In particular, Fab e20 neutralizing activity was tested against pseudoparticles derived from murine leukemia virus (MLV) displaying unmodified and functional full-length E1-E2 proteins representative of all the major HCV genotypes. In brief, HEK293T cells were cotransfected with the MLV Gag-Pol packaging vector, the MLV-luciferase reporter gene, and the plasmid expressing HCV E1E2 from different genotypes. In all experiments, control particles expressing vesicular stomatitis virus (VSV) G protein were used. Two days after transfection, the medium containing HCVpp was collected, clarified, filtered through a 0.45-μm-pore-size membrane, and used for infection of Huh-7 cells. Three days following infection, the cells were analyzed on a luminometer using the Bright-Glo™ luciferase assay kit (Promega). For all genotypes, but genotype 3 and genotype 6, the detected luminescence ranged from 10,000 to 20,000 relative luminescence units (RLU). For the neutralization assay, the HCVpp (10,000 RLU) were preincubated with different concentrations of Fab e20. The anti-HCV/NS3 Fab c33-3 was used as negative control.

The neutralizing activity of Fab e20 was also investigated using the cell culture infectious HCV (HCVcc) system, based on HCV genotype 2a strain JFH-1 [30,31]. The infectivity of JFH-1 in the presence of different concentrations of Fab e20, and of the negative-control Fab (c33-3) was determined by quantitative reverse transcription-PCR, normalizing the viral RNA against the RNA of a housekeeping gene (glyceraldehyde-3-phosphate dehydrogenase) [32].

Results and Discussion

The HCV genome encodes a mutation prone polymerase, resulting in the formation in vivo of a population of genetically...
related, but distinct variants. It is presently believed that the capacity of the virus to mutate contributes, together with the high replication rates, to the establishment of persistence. A hypervariable region (HVR1) of the HCV E2 glycoprotein has been observed to be a major determinant of isolate-specific neutralizing antibodies [33]. These antibodies provide, however, little protection against infection, due to the continuous sequence evolution of HVR1 [33]. Otherwise, it has been observed that broadly neutralizing antibodies are usually directed against highly conserved conformational epitopes of the E2 glycoprotein [21,22,24,34,35,36,37].

Fab e20 investigated in this study was able to bind HCV/E2 derived from all tested genotypes (Figure 1), indicating the highly
conserved nature of its epitope. The wide cross-reactivity of Fab e20 was also documented by immunoprecipitation of HCV/E2 on radiolabeled lysates from HEK293T cells expressing HCV surface proteins of different genotypes (data not shown). The broad cross-reactivity of Fab e20 prompted us to better characterize its epitope on HCV/E2. Previous data had already suggested that the epitope was conformationally constrained, as the Fab failed to bind either denatured HCV/E2 or multiple overlapping peptides encompassing the whole HCV/E2 sequence [23]. Moreover, Fab e20 did not show any reactivity in ELISA to five different Maltose Binding Protein-HCV/E2 fusion proteins ([E2a] - aa 304–444; [E2ab] - aa 304–512 [E2abc] - aa 304–583; [E2abcd] - aa 304–668 and [E2abcde] - aa 304–714) (Methods S1 and Table S1), or to five HVR multiple antigenic peptides [38] (MAP 291, MAP 313, MAP 442, MAP 455 and MAP 1013) (Methods S1 and Table S2), which were specifically recognized by some of the antibodies directed against linear epitopes used in this study. These data confirmed that e20 is directed against a conformational epitope which is retained only in the full length HCV/E2.

In the competition assays, Fab e20 was strongly inhibited by 9/75, a rat mAb recognizing the linear epitope 528–535 on HCV/E2 (Table 1) [39]. Fab e20 also competed with rat mAb 1/39 (436–443) and, partially, with mouse mAb AP33 (412–423), the broadest cross-reactive and cross neutralizing antibody described to date (Table 1) [26,40]. The competition with mAb 9/75 was confirmed by the fact that mutations at conserved positions 529, 530 and 535 on HCV/E2, which are located within the epitope recognized by mAb 9/75 and which are involved in the binding to CD81 [28], totally abrogated the binding of e20 (Figure 2a). These data show that these residues, highly conserved among different genotypes (Figure 2b), have a crucial role.

### Table 2. Synopsis of published anti-HCV/E2 human monoclonals binding to all major HCV genotypes (1a, 1b, 2a, 2b, 3a, 4, 5, 6).

| mAb  | Crucial residues on HCV/E2 (H77 strain) | Neutralizing activity Assay format and genotype | Antibody format | References |
|------|----------------------------------------|---------------------------------------------|-----------------|------------|
| e20  | W529, G530, D535                        | 7.5 HCVpp 1a                                | IgG1 Fab        | This paper |
|      |                                        | 7.5 HCVpp 2a                                |                 |            |
|      |                                        | 1.6 HCVpp 4                                 |                 |            |
| 1/7  | G523, W529, G530, D535                  | <1 HCVcc 2a                                 | whole IgG1      | [35]       |
| A8   | G523, W529, G530, D535                  | 0.06 HCVcc 2a                               | whole IgG1      | [35]       |
| CBH-5| C494, V497, G523, P525, G530, D535, N540, R614, H617, Y618, P619, T621, F624 | 1.77 HCVpp 1b | whole IgG1 | [37,42,43,50,51] |
|      |                                         | 0.1 HCVpp 2a                                |                 |            |
|      |                                         | 13 HCVpp 2b                                 |                 |            |
|      |                                         | 0.056 HCVcc 2a                              |                 |            |
|      |                                         | 0.04 HCVcc 2b                               |                 |            |
| CBH-7| C494, V497, N540, W549, R614, H617, Y618, P619, T621, F624 | 25.58 HCVcc 2a | whole IgG1 | [37,42,43,50,51] |
|      |                                         | 1.3 HCVcc 2b                                |                 |            |

The E2 residues involved in the binding of each antibody are reported (those crucial for e20 binding are in bold and underlined). Only the concentrations giving 50% neutralization (IC50) against HCV pseudoparticles (HCVpp) derived from different genotypes, or against HCV cell culture (HCVcc) strains, are reported. Punctual IC50 values are not available for mAbs 1:7 and A8 against HCVpp [35], and for CBH-5 and CBH-7 against HCVpp derived from genotypes 1a, 3a, 4, 5 and 6 [37,42,43,50,51]. E20 is the only monoclonal tested as Fab fragment.

doi:10.1371/journal.pone.0008254.t002
in generating the epitope recognized by Fab e20, and further indicate their importance in the production of anti-HCV/E2 broadly neutralizing antibodies [24,26,34,36,41]. On the contrary, in spite of the competition observed with AP33, mutations inside the AP33 epitope did not affect e20 binding, showing that the e20 conformational epitope does not contain the linear AP33 epitope, and that the observed competition may be mediated by steric hindrance, or by induced conformational changes of the antigen.

Fab e20 featured a potent neutralization activity against HCVpp derived from genotype 1a, with an IC50 (Fab concentration giving 50% neutralization) of 7.5 μg/ml (Figure 3a), and derived from genotypes 2a and 4, with IC50 values of 7.5 μg/ml and 1.6 μg/ml, respectively (Figure 3c and 3e). Finally, e20 was able to inhibit, albeit to a lesser extent, the infection of HCVpp 1b and 2b, with IC50 values of 15 μg/ml and 30 μg/ml, respectively (Fig. 3b and 3d). No neutralizing activity was observed against genotype 5 (UKN5.15.11). Unfortunately, it was not possible to perform the assay on genotypes 3 and 6, due to the very low and not reproducible infectivity observed for these genotypes [34]. Finally, the cross-neutralizing activity of e20 was also investigated using the cell culture infectious HCV (HCVcc) system based on HCV genotype 2a strain JFH-1 [30]. In this assay Fab e20 showed an even stronger neutralizing activity, since at a concentration as low as 1 μg/ml it was able to completely abrogate the infectivity of HCVcc (Figure 4).

Overall, the data presented here highlight that broadly cross-reactive and cross-neutralizing antibodies, as Fab e20, are generated during the natural course of HCV infection, and that they are directed against conserved epitopes on HCV/E2. We have observed that Fab e20 is able to bind all of the HCV/E2 genotypes tested, including the most phylogenetically distant genotype 2, and that it recognizes an epitope centred on three crucial residues (W529, D530 and G535). These residues, highly conserved among different HCV genotypes, are involved in E2 binding to the CD81, a possible co-receptor of HCV, and are recognized by other neutralizing antibodies [24,34,35,37]. More in details, Fab e20 is one of the few human monoclonals described to date as capable of binding all major HCV genotypes. Three of these monoclonals (1:7; A8 and CBH-5) share with e20 the residues D530 and G535 (1:7 and A8 share also W529); however, although not easily comparable because tested in different settings, they feature different neutralizing activities against different genotypes, evidencing that other residues outside those studied may play a role [42,43]. The main features of these broadly reacting antibodies, all tested as whole IgG1, are reported in Table 2 and are compared to the characteristics of e20, which has been tested as Fab fragment.

An intriguing aspect is the fact that Fab e20, although recognizing genotype 5 E2 on transfected cells, was not able to neutralize in our hands HCVpp obtained with the same glycoprotein. In theory, this can be due (i) to low sensitivity of the HCVpp neutralization assay [37] or, (ii) to the role played by residues located outside the CD81 binding site and not tested in the mutants panel, but possibly important for the neutralizing activity of e20 against genotype 5 [44].

Finally, it is important to note that e20 biological activity was tested using the antibody as a Fab fragment, and that its activity may increase in the whole immunoglobulin format [45]. That may result in increased neutralizing potency not only to genotypes 1a, 2a and 4, but also to genotypes 1b and 2b. Moreover, the better knowledge of the broadly neutralizing epitopes on HCV/E2 glycoprotein, and the availability of a panel of antibodies with broadly neutralizing characteristics, similar to those observed for e20, may also allow the use of a balanced combination of neutralizing antibodies, thus resulting in a synergic enhancement of the overall neutralizing activity (as already observed with HIV) [46,47,48,49].

Supporting Information

Table S1 Binding of e20 Fab to maltose binding protein-E2 fusion constructs (O.D.450). The human Fab C33 directed against HCV/NS3 was used as negative control; mouse Mabs 7/59, 7/16b and 6/53 were used as positive controls.

Found at: doi:10.1371/journal.pone.0008254.s001 (0.03 MB DOC)

Table S2 Binding of human anti-HCV/E2 Fab e20 to multiple antigenic peptides (MAP) (O.D.450). The sequence of each MAP is reported. The human Fab C33 was used as negative control; mouse Mabs 7/59 and 9/27 were used as positive controls.

Found at: doi:10.1371/journal.pone.0008254.s002 (0.03 MB DOC)

Methods S1 Binding of human anti-HCV/E2 Fab e20 to Maltose Binding Protein (MBP)-HCV/E2 fusion proteins. Binding of human anti-HCV/E2 Fab e20 to Hypervariable region 1 (HVR1) multiple antigenic peptides.

Found at: doi:10.1371/journal.pone.0008254.s003 (0.02 MB DOC)

Author Contributions

Conceived and designed the experiments: NM RAD MP GC RB. Performed the experiments: RAD MP GS. Analyzed the data: NM RAD MP MC RB. Contributed reagents/materials/analysis tools: AP JB. Wrote the paper: NM MP MG RB.

References

1. Soriano V, Peters MG, Zeuzem S (2009) New therapies for hepatitis C virus infection. Clin Infect Dis 48: 315–320.
2. Webster DP, Klenerman P, Collie J, Jeffrey KJ (2009) Development of novel treatments for hepatitis C. Lancet Infect Dis 9: 100–117.
3. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, et al. (1993) Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 74 (Pt1): 2391–2399.
4. Timm J, Roggendorf M (2007) Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J Gastroenterol 13: 4800–4817.
5. Lavillette D, Farr AW, Vossen C, Donot P, Bartsch B, et al. (2005) Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 41: 265–274.
6. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, et al. (2000) The outcome of infection. J Virol 74: 4327–4334.
7. Manzini A, Solfrizzi L, Debiaggi M, Zara F, Tani E, et al. (2000) Dominant role of host selective pressure in driving hepatitis C virus evolution in perinatal infection. J Virol 74: 4327–4334.
8. Bowen DG, Walker CM (2005) The origin of quasispecies: cause or consequence of chronic hepatitis C viral infection? J Hepatol 42: 408–417.
9. Gerlach JT, Diepolder HM, Jung MC, Grauer NH, Schraut WW, et al. (1999) Recurrence of hepatitis C virus after loss of virus-specific CD8+ T-cell response in acute hepatitis C. Gastroenterology 117: 933–941.
10. Grauer NH, Lechner F, Jung MC, Diepolder H, Gerlach T, et al. (2001) Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 75: 5550–5558.
11. Thimm R, Oldach D, Chang KM, Steiger C, Ray SC, et al. (2001) Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194: 1395–1406.
12. Llosa C, Major ME, Heydach D, Heyward S, Talal A, et al. (2004) Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A 101: 10149–10154.
13. Manns MC, Liang TJ, Hezode C, O'Connor S, Tanne D, et al. (2005) Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A 102: 4560–4565.
Neutralizing Anti-HCV Fab

14. Bartosch B, Buhk J, Mennier JC, Grandier C, Eugele RE, et al. (2003) In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A 100: 14199–14204.

15. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, et al. (1994) Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 91: 7792–7796.

16. Farci P, Shimoda A, Wong D, Cabezon T, De Giovannis D, et al. (1996) Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A 93: 15394–15399.

17. Ishii K, Rosa D, Watanabe Y, Katsuya T, Harada H, et al. (1998) High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 28: 1117–1120.

18. Piazza M, Sagiozza L, Tsone G, Guadagnino V, Stazi MA, et al. (1997) Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med 157: 1537–1544.

19. Bugli F, Mancini N, Kang CY, DiCampi C, Greco A, et al. (2001) Mapping B cell epitopes of Hepatitis C Virus E2 glycoprotein using human monoclonal antibodies from phage display libraries. J Virol 85.

20. Burioni R, Bugli F, Mancini N, Rosa D, DiCampi C, et al. (2001) Non-neutralizing human antibody fragments against Hepatitis C Virus E2 Glycoprotein Modulate Neutralization of Binding Activity of Human Recombinant Fab. Virology 282: 29–35.

21. Burioni R, Mancini N, Carletti S, Perotti M, Greco A, et al. (2004) Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection. Virology 327: 242–248.

22. Burioni R, Matsuura Y, Mancini N, Tani H, Miyamura T, et al. (2002) Diverging effects of human recombinant anti-hepatitis C virus (HCV) antibody fragments derived from a single patient on the infectivity of a vesicular stomatitis virus/HCV pseudotype. J Virol 76: 11775–11779.

23. Burioni R, Piaissat P, Mancini A, Rosa D, Delli Carri V, et al. (1998) Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments. Hepatology 28: 810–814.

24. Perotti M, Mancini N, Diotti RA, Tarr AW, Ball JK, et al. (2008) Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol 82: 1047–1052.

25. Piaissat P, Burioni R, Mancini A, Salofrosi L, Candela M, et al. (1997) Human monoclonal recombinant Fab specific for HCV antigens obtained by repertoire cloning in phage display combinatorial vectors. Res Virol 148: 163–169.

26. Owsianka A, Tarr AW, Jutla VS, Lavillette D, Bartosch B, et al. (2005) Monoclonal antibody AP53 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 79: 11095–11104.

27. Prabhu R, Khalap N, Burioni R, Clementi M, Garry RF, et al. (2004) Inhibition of hepatitis C virus nonstructural protein, helicase activity, and viral replication by a recombinant human antibody clone. Am J Pathol 165: 1163–1173.

28. Owsianka AM, Timmus JM, McCleire CP, Brown RJ, et al. (2006) Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 43: 592–601.

29. Allander T, Drakenberg K, Beyer A, Rosa D, Abrignani S, et al. (2000) Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. J Gen Virol 81: 2451–2459.

30. Jacob RE, Keck Z, Ohno O, Young SK, Tomer KB (2008) Structural elucidation of critical residues involved in binding of human monoclonal antibodies to hepatitis C virus E2 envelope glycoprotein. Biochem Biophys Acta 1784: 330–342.

31. Keck Z, Li TK, Xia J, Gal-Tanamy M, Ohno O, et al. (2008) Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol 82: 6061–6066.

32. Zhang P, Zhong L, Struble ER, Watanabe H, Kachko A, et al. (2009) Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci U S A.

33. Zhang MY, Xiao X, Sidorov IA, Choudhry V, Cham F, et al. (2004) Identification and characterization of a new cross-reactive human immuno- modulator virus type 1-neutralizing human monoclonal antibody. J Virol 78: 9235–9242.

34. Buchbinder A, Karwowska S, Gorny MK, Burda ST, Zolla-Pazner S (1992) Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains. AIDS Res Hum Retroviruses 8: 425–427.

35. Lal S, Burda S, Gorny MK, Karwowska T, Buchbinder A, et al. (1994) Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J Virol 68: 4001–4009.

36. Tilley SA, Honnen WJ, Racho ME, Chou TC, Pinter A (1992) Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. AIDS Res Hum Retroviruses 8: 461–467.

37. Vijh-Warrier S, Pinter A, Honnen WJ, Tilley SA (1996) Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site. J Virol 70: 4466–4473.

38. Keck Z, Op De Beek A, Hadlock KG, Xia J, Li TK, et al. (2004) Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J Virol 78: 9232–9236.

39. Keck Z, Xia J, Cai Z, Li TK, Owsianka AM, et al. (2007) Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol 81: 1045–1047.